


### REMARKS

The foregoing amendments to claims 6, 7 and 9 are supported throughout the specification. New claim 29 is dependent upon claim 7, and it is supported by original claim 9. New claim 30 recites that the genes are inactivated by deletion of a portion of the coding region of the gene, and this recitation is supported in the specification at page 11, lines 18-24. New claims 31 and 32 are directed to vaccine compositions that comprise attenuated *Salmonella* bacteria selected from the group consisting of *S. dublin*, *S. choleraesuis*, *S. typhimurium*, and *S. newport*. The recited strains of bacteria are supported throughout the specification, particularly at page 6, lines 21-30. These amendments do not introduce new matter to the application.

Prosecution has been closed in the present application and a Notice of Allowance has issued, indicating that claims 6, 7 and 9 are in condition for allowance. The Applicants respectfully request entry of the foregoing amendment and attached Information Disclosure Statement as responsive documents accompanying a Request for Continued Prosecution (filed herewith). This Request for Continued Prosecution is timely filed prior to the due date for paying the issue fee (January 22, 2003). Pursuant to 37 C.F.R. § 1.114, attached herewith is a check for \$770.00 in payment of the fee set out in 37 C.F.R. § 1.17(2). The Commissioner is hereby authorized to charge any additional fees due to Deposit Account 13-2855. A copy of this paper is enclosed.

Dated: November 25, 2003

Respectfully submitted,

By   
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Agents for Applicant